Eisai Says Alzheimer’s Drug Shows Benefit on Amyloid-Beta, Tau

Eisai says further analysis of a phase 3 study of its Alzheimer’s drug lecanemab showed benefits on amyloid-beta and tau, 2 underlying pathological hallmarks of the disease.

• In addition to primary and key secondary endpoints, study also measured multiple biomarkers involved in the pathophysiology of Alzheimer’s including amyloid, tau and neurodegeneration
  • Biomarkers improved after treatment with lecanemab, suggesting the drug exerts biological effects that demonstrate slowing of disease progression
• Eisai also says subcutaneous lecanemab is predicted to achieve comparable efficacy and lower incidence of amyloid-related imaging abnormalities with edema/effusion compared with intravenous lecanemab
• Related Story: Medicare Proposes Expanding Patient Access ...